57149-07-2

57149-07-2 structure

Name: Naftopidil
Chemical Name: Naftopidil dihydrochloride
CAS Number: 57149-07-2
Molecular Formula: C₂₄H₂₈N₂O₃
Molecular Weight: 392.491
Catalog: API Circulatory system medication Prevention and treatment of angina pectoris
Create Date: 2018-03-09 08:00:00
Modify Date: 2026-07-01 21:21:10
Naftopidil (Flivas), a selective α1-adrenergic receptor antagonist or alpha blocker, is an antihypertensive drug.Target: α1-Adrenergic ReceptorNaftopidil significantly improved the overall international prostatic symptom score ; from 19.2±7.9 to 11.7±5.8 in the M group and from 19.4±6.4 to 12.3±6.8 in the E group (p<0.0001), QOL score from 4.9±0.8 to 3.2±1.4 in the M group and from 5.0±0.8 to 3.6±1.3 in the E group (p<0.0001), and OAB symptom score from 7.8±2.6 to 5.0±2.5 in the M group (p<0.0001) and from 8.6±2.9 to 5.8± 3.3 in the E group (p<0.0001). naftopidil improves storage symptoms as well as voiding symptoms regardless of timing of administration [1]. The selectivity of naftopidil for prostatic pressure was the most potent among the test compounds. In addition, using cloned human alpha1-adrenoceptor subtypes, naftopidil was selective for the alpha1d-adrenoceptor with approximately 3- and 17-fold higher affinity than for the alpha1a- and alpha1b-adrenoceptor subtypes, respectively. The selectivity of naftopidil for prostatic pressure may be attributable to its high binding affinity for alpha1a- and alpha1d-adrenoceptor subtypes [2].

Name	Naftopidil dihydrochloride
Synonyms	4-(2-methoxyphenyl)-α-[(1-naphthalenyloxy)methyl]-1-piperazineethanol dihydrochloride Naftopidil, 10 mM in DMSO Naftopidil> Naftopidildihydrochloride Nafitopidil BM-15275 Naftopidil a selective α1-adrenergic rector antagonist Flivas (+-)-1-(4-(2-methoxyphenyl)piperazinyl)-3-(1-naphthyloxy)propan-2-ol (R)-1-(1-Naphtyloxy)-3-[4-(2-methoxyphenyl)piperazino]-2-propanol (S)-1-(1-Naphtyloxy)-3-[4-(2-methoxyphenyl)piperazino]-2-propanol 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(naphthalen-1-yloxy)propan-2-ol NAFTOPIDIL DIHYDROCHLORIDE (KT-611) A1 A DRENOCTOR ANTAG 1-[4-(2-Methoxyphenyl)piperazin-1-yl]-3-(1-naphthyloxy)propan-2-ol Naftopiil 1-[4-(2-Methoxyphenyl)-1-piperazinyl]-3-(1-naphtyloxy)-2-propanol Naftopidil hydrochlo 4-(2-Methoxyphenyl)-α-[(1-naphthalenyloxy)methyl]-1-piperazineethanol hydrochloride hydrate 1-[4-(2-Methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxy-propan-2-ol 4-(2-methoxyphenyl)-alpha-((1-naphthalenyloxy)methyl)-1-pioerazineethanol Naftopidil hydrate hydrochloride NaftopidilQ: What is Naftopidil Q: What is the CAS Number of Naftopidil Q: What is the storage condition of Naftopidil Q: What e the applications of Naftopidil 4-(2-Methoxyphenyl)-alpha-[(1-naphthalenyloxy)methyl]-1-piperazineethanol [R,(+)]-1-[4-(2-Methoxyphenyl)-1-piperazinyl]-3-(1-naphtyloxy)-2-propanol 1-[4-(2-Methoxyphenyl)-1-piperazinyl]-3-(1-naphthyloxy)-2-propanol Naftopidil - Bio-X Naftopidil and intermediates KT-611, 4-(2-Methoxyphenyl)-α-[(1-naphthalenyloxy)methyl]-1-piperazineethanol hydrate hydrochloride rac-4-(2-Methoxyphenyl)-a-[(1-naphthalenyloxy)methyl]-1-piperazineethanol Dihydrochloride 3-[4-(2-Methoxyphenyl)piperazinyl]-1-naphthyloxypropan-2-ol 1-Piperazineethanol, 4-(2-methoxyphenyl)-a-[(1-naphthalenyloxy)methyl]- (9CI) Naftopidil Naftopidil 4-(2-methoxyphenyl)-alpha-((1-naphthalenyloxy)methyl)-1-pioerazineethano Naftopidil Dihydrochloride See: N213501 1-(2-Methoxyphenyl)-4-[3-(naphth-1-yloxy)-2-hydroxypropyl]-piperazine NAFTOPIDIL 4-(2-Methoxyphenyl)-alpha-[(1-naphthalenyloxy)methyl]-1-piperazineethanol dihydrochloride Naftopil CAS No:57-2 1-Piperazineethanol,4-(2-Methoxyphenyl)-a-[(1-naphthalenyloxy)Methyl] Naftopidil hydrochloride hydrate Avishot [S,(-)]-1-[4-(2-Methoxyphenyl)-1-piperazinyl]-3-(1-naphtyloxy)-2-propanol 4-(2-Methoxyphenyl)-α-[(1-naphthalenyloxy)methyl]-1-piperazineethanolhydrochloride RS-1-[4-(2-Methoxyphenyl)-1-piperazinyl]-3-(1-naphthoxy)-2-propanol 1-Piperazineethanol, 4-(2-methoxyphenyl)-α-[(1-naphthalenyloxy)methyl] Naftopidil dihydrochloride/Naftopidil Naftopidil hydrochloride, alpha1 Adrenoctor antagonist Naftopidil(Flivas) 4-(2-Methoxyphenyl)-α-[(naphthalen-1-yloxy)methyl]piperazine-1-ethanol 4-(2-Methoxyphenyl)-a-[(1-naphthalenyloxy)methyl]-1-piperazineethanol NafTopIDi1 4-(2-Methoxyphenyl)-α-[(1-naphthalenyloxy)methyl]-1-piperazineethanol rac-4-(2-Methoxyphenyl)-α-[(1-naphthalenyloxy)methyl]-1-piperazineethanol Dihydrochloride MFCD00242741 kt-611 1-[4-(2-methoxyphenyl)-1-piperazinyl]-3-(1-naphthalenyloxy)-2-propanol dihydrochloride Naftopidil D7Q: What is Naftopidil D7 Q: What is the CAS Number of Naftopidil D7 Q: What is the storage condition of Naftopidil D7 Q: What e the applications of Naftopidil D7

Description	Naftopidil (Flivas), a selective α1-adrenergic receptor antagonist or alpha blocker, is an antihypertensive drug.Target: α1-Adrenergic ReceptorNaftopidil significantly improved the overall international prostatic symptom score ; from 19.2±7.9 to 11.7±5.8 in the M group and from 19.4±6.4 to 12.3±6.8 in the E group (p<0.0001), QOL score from 4.9±0.8 to 3.2±1.4 in the M group and from 5.0±0.8 to 3.6±1.3 in the E group (p<0.0001), and OAB symptom score from 7.8±2.6 to 5.0±2.5 in the M group (p<0.0001) and from 8.6±2.9 to 5.8± 3.3 in the E group (p<0.0001). naftopidil improves storage symptoms as well as voiding symptoms regardless of timing of administration [1]. The selectivity of naftopidil for prostatic pressure was the most potent among the test compounds. In addition, using cloned human alpha1-adrenoceptor subtypes, naftopidil was selective for the alpha1d-adrenoceptor with approximately 3- and 17-fold higher affinity than for the alpha1a- and alpha1b-adrenoceptor subtypes, respectively. The selectivity of naftopidil for prostatic pressure may be attributable to its high binding affinity for alpha1a- and alpha1d-adrenoceptor subtypes [2].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor Research Areas >> Cardiovascular Disease
References	[1]. Sakai, H., et al., [Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication]. Hinyokika Kiyo [2]. Takei, R., et al., Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn J Pharmacol, 1999. 79(4): p. 447-54.

Density	1.2±0.1 g/cm3
Boiling Point	602.8±55.0 °C at 760 mmHg
Melting Point	127 °C
Molecular Formula	C₂₄H₂₈N₂O₃
Molecular Weight	392.491
Flash Point	318.3±31.5 °C
Exact Mass	392.209991
PSA	45.17000
LogP	4.81
Vapour Pressure	0.0±1.8 mmHg at 25°C
Index of Refraction	1.619
Storage condition	Store at RT
Water Solubility	methanol: >10 mg/mL

CHEMICAL IDENTIFICATION

RTECS NUMBER :: TL9336500

CHEMICAL NAME :: 1-Pioerazineethanol, 4-(2-methoxyphenyl)-alpha-((1-naphthalenyloxy)methyl) -

CAS REGISTRY NUMBER :: 57149-07-2

BEILSTEIN REFERENCE NO. :: 0629965

LAST UPDATED :: 199806

DATA ITEMS CITED :: 4

MOLECULAR FORMULA :: C24-H28-N2-O3

MOLECULAR WEIGHT :: 392.54

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 4320 mg/kg

SEX/DURATION :: female 16 day(s) after conception - 21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Maternal Effects - other effects Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 48,7,1994

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1080 mg/kg

SEX/DURATION :: female 16 day(s) after conception - 21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 48,7,1994

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 15680 mg/kg

SEX/DURATION :: male 9 week(s) pre-mating female 2 week(s) pre-mating - 3 week(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 48,17,1994

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1300 mg/kg

SEX/DURATION :: female 7-19 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - other effects Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 48,1,1994

Hazard Codes	Xi
WGK Germany	3
RTECS	TL9336500
HS Code	2942000000

Precursor 4
2461-42-9 35386-24-4 90-15-3 90-04-0
DownStream 0

HS Code	2942000000

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

744240-29-7	913692-28-1
920364-48-3	565206-92-0
873013-85-5	339029-13-9
835898-52-7	861206-16-8
733791-48-5	381704-62-7